Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Eli Lilly reports 94% Lp(a) reduction with lepodisiran in Phase 2 trials, targeting inherited heart disease risk.

The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...

The growing interest in Mounjaro shows an increasing awareness of metabolic health, which is a positive trend. However, ...

Recently, the weight loss drug introduced by Eli Lilly, Mounjaro, has been launched in India sparking a debate among health experts ...

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...